"Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims"
Semaglutide users in the STEP 1 trial lost an average of 14.9% of their body weight over 68 weeks
Keywords: gastrointestinal motility, glp-1 receptor agonist, medical weight loss, postoperative adhesions, semaglutide, small bowel obstruction Introduction Small bowel obstruction (SBO) can arise from a variety of mechanical or functional causes, each with important implications for clinical management and the potential need for timely surgical intervention [1]
Cost : Tablets and injections vary in price depending on dosage, brand, and insurance coverage, making affordability a critical consideration
Common Side Effects Most side effects are gastrointestinal and typically occur during the titration phase (the first 1620 weeks when your dose is slowly increasing): Very Common: Nausea (affects ~44% of users), diarrhea, vomiting, and constipation